Rather, testing at 6 months and then annually or biannually, would be beneficial, as it would serve to identify the 5 percent of new patients who develop DSA annually. Once these patients are identified, studies have shown that preemptive treatment to a goal of antibody clearance can be used to improve graft function and survival. In addition to screening for new DSA, monitoring for clearance of DSA along with histologic reversal of rejection in patients with AMR is important. In sum, there is substantial evidence suggesting that all patients need to have some monitoring for DSA to identify new onset of DSA or clearance of DSA. Additionally, in all DSA scenarios, treatment of persistent DSA is important, as it can lead to improved allograft survival.
Parent Category: Post-Transplant Outcomes